cytarabine has been researched along with Carcinoma, Pancreatic Ductal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brody, JR; Costantino, CL; Cozzitorto, JA; Dasgupta, A; Gorospe, M; Keen, JC; Kennedy, EP; Kuwano, Y; Witkiewicz, AK; Yeo, CJ | 1 |
| Adams, J; Blaszkowsky, LS; DeLaney, TF; Fernandez-Del Castillo, C; Hong, TS; Kwak, EL; Mamon, HJ; Mino-Kenudson, M; Ryan, DP; Winrich, B; Yeap, B | 1 |
1 trial(s) available for cytarabine and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head.
Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Cytarabine; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Length of Stay; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prescriptions; Prospective Studies; Proton Therapy; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2011 |
1 other study(ies) available for cytarabine and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Topics: Antigens, Surface; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; ELAV Proteins; ELAV-Like Protein 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inactivation, Metabolic; Pancreatic Neoplasms; RNA-Binding Proteins; Time Factors; Treatment Outcome; Tumor Cells, Cultured; Up-Regulation | 2009 |